Drug Profile
MM 111
Alternative Names: MM-111Latest Information Update: 08 Apr 2020
Price :
$50
*
At a glance
- Originator Merrimack Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Recombinant fusion proteins
- Mechanism of Action ERBB 2 receptor antagonists; ERBB-3 receptor antagonists; Neuregulin-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastric cancer; HER2 positive breast cancer; Oesophageal cancer; Solid tumours
Most Recent Events
- 30 May 2019 Merrimack Pharmaceuticals enters into an agreement with Elevation Oncology to divest MM 111 for Cancer
- 26 Feb 2015 9175306 - Merrimack stops enrolment in phase II trial
- 26 Feb 2015 Discontinued - Phase-I for HER2-positive-breast cancer (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV)